GIP and type 2 diabetes mellitus: Contrary to GLP-1 analogues, the studies in mouse models of T2DM treated with GIP analogues used in monotherapy did not reach the clinical phase because of the conflicting results in body weight, glucose disposal, and energy expenditure.